Form 8-K - Current report:
SEC Accession No. 0001140361-22-000588
Filing Date
2022-01-05
Accepted
2022-01-05 06:06:26
Documents
12
Period of Report
2022-01-03
Items
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 8-K brhc10032515_8k.htm   iXBRL 8-K 26406
  Complete submission text file 0001140361-22-000588.txt   163866

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA btx-20220103.xsd EX-101.SCH 3929
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20220103_lab.xml EX-101.LAB 22544
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20220103_pre.xml EX-101.PRE 16047
6 EXTRACTED XBRL INSTANCE DOCUMENT brhc10032515_8k_htm.xml XML 4246
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 22509330
SIC: 2834 Pharmaceutical Preparations